Trial Profile
A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Dec 2022
Price :
$35
*
At a glance
- Drugs Efpeglenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms AMPLITUDE-M
- Sponsors Hanmi Pharmaceutical; Sanofi
- 07 Jun 2022 Results published in the Diabetes Care
- 29 Jun 2021 Primary endpoint ( (Change in glycated hemoglobin (HbA1c) (%))) has been met, according to Results presented at the 81st Annual Scientific Sessions of the American Diabetes Association.
- 29 Jun 2021 Results presented at the 81st Annual Scientific Sessions of the American Diabetes Association.